10.1016/j.diabres.2023.110605 16 LiuL.ChenJ.WangL.ChenC
March 19, 2026: FDA approves Wegovy HD (semaglutide 7.2 mg injection)
Infections: vulvovaginal candidiasis, bacterial vaginosis, vulvovaginitis Comparative observational signal (protective association): In a phenome-wide association study comparing people with type 2 diabetes prescribed GLP-1 receptor agonists vs SGLT2 inhibitors and DPP4 inhibitors (NIH All of Us cohort, Jan 2018Oct 2023), semaglutide prescription was associated with reduced risk of diagnoses including candidiasis of vulva and vagina and inflammatory disease of cervix, vagina, and vulva compared with SGLT2 inhibitors
Wegovy: Tambin desarrollado por Novo Nordisk, Wegovy (inyeccin de semaglutida) es una formulacin de dosis ms alta de semaglutida aprobada especficamente para el control crnico del peso en adultos con obesidad o sobrepeso que tienen al menos una comorbilidad relacionada con el peso
Patients should be provided with a letter from their healthcare provider or pharmacy documenting the medical necessity of carrying injection supplies